Tirzepatide Explored for Weight Loss in Early Breast Cancer Patients

Obesity is a significant risk factor for Hormone Receptor-Positive/HER2-Negative (HR+/Her2-) breast cancer recurrence and can negatively impact treatment outcomes for patients undergoing adjuvant therapy. Effective weight management strategies are crucial, yet often challenging to implement in this vulnerable population. This study addresses the critical need to evaluate the feasibility, safety, and efficacy of novel pharmacological interventions like tirzepatide for weight loss in early-stage HR+/Her2- breast cancer patients.

As this is a recruiting clinical trial, specific results are not yet available. However, the study aims to determine if tirzepatide can effectively induce a 5% or more body weight reduction in HR+/Her2- breast cancer patients. Researchers will assess the safety profile of tirzepatide and its tolerability, measured by discontinuation rates and treatment completion. Secondary objectives include evaluating the impact of weight loss on 3-year invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), as well as changes in BMI, body fat distribution, metabolic markers, and circulating tumor DNA (ctDNA). The primary objective is to establish the feasibility of achieving a clinically significant 5% or more body weight reduction in this specific cancer patient population using tirzepatide.